The price could be right for these stocks.
EXEL earnings call for the period ending September 30, 2024.
For Immediate ReleaseChicago, IL – October 25, 2024 – Today, Zacks Equity Research discusses Exelixis, Inc, EXEL, Blueprint Medicines BPMC, CRISPR Therapeutics CRSP, Amicus Therapeutics FOLD and Verona...
It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major...
The midcap biotech just became an even better buy.
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.Here's...
/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Despite Incyte’s underperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
No need to break the bank to get in on these likely long-term winners.
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – The surge in...